MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6506-1517-1525$20.00
Mol Pharmacol 65:1517-1525, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lattard, V.
Right arrow Articles by Cashman, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lattard, V.
Right arrow Articles by Cashman, J. R.

Alternative Processing Events in Human FMO Genes

Virginie Lattard, Jun Zhang, and John R. Cashman

Human BioMolecular Research Institute, San Diego, California

In humans, flavin-containing monooxygenase (FMO) functional diversity is determined by the expression of five FMO genes, named FMO1 to FMO5, and their variants. In this study, we systematically analyzed transcripts of FMO1 to FMO5 in different human tissues by reverse-transcription-polymerase chain reaction and identified a large number of splice variants. Exon skipping was the major splicing event observed. Normally spliced transcripts were generally the prominent transcript detected. For FMO1, FMO2, and FMO3, two to three different splice variants were identified, and their corresponding expression was always low in the tissues examined. For FMO5 and particularly for FMO4, more complex alternative splice patterns were observed, with five and seven splice variants detected, respectively. Most identified FMO splice variants either caused a frame-shift or lacked essential functional sites. The corresponding transcripts were therefore incapable of encoding a functional enzyme and were not analyzed further in this study. However, a common in-frame exon 3- (exon 4 for FMO4) deleted variant, leading to the deletion of 63 amino acids, was identified for FMO1, FMO3, FMO4, and FMO5. To examine the functional importance of exon 3-deletion, FMO1, FMO3, FMO4 and the corresponding exon-deleted proteins were expressed as fusion proteins. Activity studies were done with two selective functional FMO substrates, methimazole, and 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine and exon 3- (exon 4 for FMO4) deleted FMOs were not able to catalyze the S- and N-oxygenation of these substrates, respectively. It is not clear whether these FMO splice variants can oxygenate other substrates, including those that remain to be discovered.


Received December 2, 2003; accepted March 9, 2004

Address correspondence to: John R. Cashman; Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego CA, 92121. E-mail: jcashman{at}hbri.org




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
G. Rodriguez-Fuentes, R. Aparicio-Fabre, Q. Li, and D. Schlenk
Osmotic Regulation of a Novel Flavin-Containing Monooxygenase in Primary Cultured Cells from Rainbow Trout (Oncorhynchus mykiss)
Drug Metab. Dispos., July 1, 2008; 36(7): 1212 - 1217.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Alfieri, E. Malito, R. Orru, M. W. Fraaije, and A. Mattevi
Revealing the moonlighting role of NADP in the structure of a flavin-containing monooxygenase
PNAS, May 6, 2008; 105(18): 6572 - 6577.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Borbas, J. Zhang, M. A. Cerny, I. Liko, and J. R. Cashman
Investigation of Structure and Function of a Catalytically Efficient Variant of the Human Flavin-Containing Monooxygenase Form 3
Drug Metab. Dispos., December 1, 2006; 34(12): 1995 - 2002.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. Zhang and J. R. Cashman
QUANTITATIVE ANALYSIS OF FMO GENE mRNA LEVELS IN HUMAN TISSUES
Drug Metab. Dispos., January 1, 2006; 34(1): 19 - 26.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. B. Koukouritaki, M. T. Poch, E. T. Cabacungan, D. G. McCarver, and R. N. Hines
Discovery of Novel Flavin-Containing Monooxygenase 3 (FMO3) Single Nucleotide Polymorphisms and Functional Analysis of Upstream Haplotype Variants
Mol. Pharmacol., August 1, 2005; 68(2): 383 - 392.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics